切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2017, Vol. 11 ›› Issue (05) : 433 -436. doi: 10.3877/cma.j.issn.1674-1358.2017.05.002

综述

HBV与HCV共感染者的抗病毒治疗进展
陈羽婷1, 杨松1,†(), 成军1   
  1. 1. 100015　北京，首都医科大学附属北京地坛医院肝病三科
  • 收稿日期:2017-04-27 出版日期:2017-10-15
  • 通信作者: 杨松
  • 基金资助:
    北京市卫生系统高层次卫生技术人才队伍建设专项经费(No. 2016-108); 登峰计划项目（肝病专业）(No. DFL20151701); 首都卫生发展科研专项项目(No. 2014-2-2172)

Progress in antiviral therapy in patients with HBV/HCV co-infection

Yuting Chen1, Song Yang1,†(), Jun Cheng1   

  1. 1. Division 3 of Center of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
  • Received:2017-04-27 Published:2017-10-15
  • Corresponding author: Song Yang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈羽婷, 杨松, 成军. HBV与HCV共感染者的抗病毒治疗进展[J]. 中华实验和临床感染病杂志(电子版), 2017, 11(05): 433-436.

Yuting Chen, Song Yang, Jun Cheng. Progress in antiviral therapy in patients with HBV/HCV co-infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(05): 433-436.

乙型肝炎病毒或丙型肝炎病毒共感染是病毒性肝炎临床诊疗和研究的热点之一。与单纯乙型肝炎病毒或丙型肝炎病毒感染相比，乙型肝炎病毒/丙型肝炎病毒共感染者往往病情进展更为迅速，预后更差。在直接作用抗病毒药物应用于临床之前，聚乙二醇化干扰素+利巴韦林核苷（酸）类似物治疗是这些患者治疗的主要方案。随着直接作用抗病毒药物的不断进展，直接作用抗病毒药物核苷（酸）类似物的方案在临床上应用的证据不断积累。尤其是直接作用抗病毒药物治疗过程中部分共感染者出现乙型肝炎病毒激活的问题，备受临床广泛关注。现就HBV/HCV共感染者的抗病毒治疗进展进行综述。

关键词: 肝炎病毒, 乙型, 肝炎, 丙性, 慢性, 抗病毒药, 预后

Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is one of the key area in research and clinical practice of viral hepatitis. When compared with single HBV or HCV infection, HBV/HCV co-infection patients show more rapid diseases progression and worse prognosis. Before Direct-acting antivirals (DAAs) were available, Pegylated interferon (PegIFN) + ribavirin nucleos(t)ide analogues (NAs) are first-line therapy for theses patients. Yet, with the development of DAAs, data of DAAs NAs for HBV/HCV co-infection patients were also accumulated. Especially cases about HBV activation after HCV eradiation in HBV/HCV co-infection patients were recently reported, which draw attention of clinics. So the current data about antiviral therapy in HBV/HCV coinfection patients were reviewed.

Key words: Hepatitis B virus, Hepatitis C, Chronic, antiviral agents, prognosis
[1]
Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection[J]. World J Gastroenterol,2014,20(40):14559- 14567.
[2]
Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment[J]. J Gastroenterol Hepatol,2008,23(4):512-520.
[3]
Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection[J]. World J Gastroenterol, 2014,20(11):2955-2961.
[4]
Hamzaoui L, El Bouchtili S, Siai K, et al. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge[J]. Clin Res Hepatol Gastroenterol,2013,37(1):e16-e20.
[5]
Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection[J]. Expert Opin Pharmacother,2010,11(6):919-928.
[6]
Liu C J, Chu Y T, Shau W Y, et al. Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality[J]. Gut,2014,63(3):506-514.
[7]
Yu ML, Lee CM, Chen CL, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up[J]. Hepatology,2013,57(6):2135-2142.
[8]
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016[J]. J Hepatol,2017,66(1):153-194.
[9]
De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge[J]. J Clin Virol,2016,78(1):27-30.
[10]
Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir[J]. Clin Infect Dis,2015,61(8):1304-1306.
[11]
Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report[J]. J Med Case Rep,2015,9(1):164.
[12]
Mekky MA, Nasr AM, Saleh MA, et al. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients[J]. Arab J Gastroenterol,2013,14(4):143-147.
[13]
Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management[J]. Ann Gastroenterol,2015,28(2):221-228.
[14]
Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection[J]. World J Gastroenterol,2014,20(40):14559- 14567.
[15]
Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C[J]. J Clin Oncol,2011,29(27):3643-3650.
[16]
Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients[J]. Hepatology,2006,43(1):100-107.
[17]
Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin[J]. Scand J Gastroenterol,2009,44(12):1487-1490.
[18]
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
[19]
Liu CJ, Chen PJ, Chen DS, et al. Perspectives on dual hepatitis B and C infection in Taiwan[J]. J Formos Med Assoc,2016,115(5):298-305.
[20]
Yeh ML, Hung CH, Huang JF, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses[J]. PLoS One,2011,6(6):e20752.
[21]
Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis[J]. Virol J,2012,9:186.
[22]
Coppola N, Stanzione M, Messina V, et al. DAA-based regimens in HBsAg/anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation[J]. J Hepatol,2017,66(Suppl 1):727.
[23]
Preda C, Popescu C, Constantinescu I, et al. Outcome of patients with compensated liver cirrhosis with hepatitis B virus + hepatitis C virus coinfection treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: a national cohort study[J]. J Hepatol,2017,66(Suppl 1):295-296.
[24]
Wang C, Li B, Chen J, et al. Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis[J]. Hepatology,2016,64(Suppl 1):461A.
[25]
Wahle R C, Perez R M, Pereira P F, et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection[J]. Braz J Infect Dis,2015,19(5):533-537.
[26]
Coppola N, Pisapia R, Tonziello G, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection[J]. Antivir Ther,2008,13(2):307-318.
[27]
Pontisso P, Gerotto M, Benvegnu L, et al. Coinfection by hepatitis B virus and hepatitis C virus[M]. 1998:137-142.
[28]
Londoño MC, Lens S, Mariño Z, et al. Hepatitis B (HBV) reactivation during anti-hepatitis C (HCV) therapy with interferon (IFN)-free regimens: a prospective study[J]. Hepatology,2016,64(Suppl 1):297A.
[29]
Kawagishi N, Suda G, Onozawa M, et al. Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C[J]. J Hepatol,2017,66(Suppl 1):725-726.
[30]
Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals[J]. Hepatology,2017,66(1):27-36.
[31]
Chen GF, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and metaanalysis[J]. J Hepatol,2017,66(Suppl 1):296-297.
[1] 高建松, 陈晓晓, 冯婷, 包剑锋, 魏淑芳, 潘林. 基于超声瞬时弹性成像的多参数决策树模型评估慢性乙型肝炎患者肝纤维化等级[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 923-929.
[2] 张思平, 刘伟, 马鹏程. 全膝关节置换术后下肢轻度内翻对线对疗效的影响[J]. 中华关节外科杂志(电子版), 2023, 17(06): 808-817.
[3] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[4] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[5] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[6] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[7] 何吉鑫, 杨燕妮, 王继伟, 李建国, 谢铭. 肠道菌群及肠道代谢产物参与慢性便秘发生机制的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 495-499.
[8] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[9] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[10] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[11] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[12] 易成, 韦伟, 赵宇亮. 急性肾脏病的概念沿革[J]. 中华临床医师杂志(电子版), 2023, 17(08): 906-910.
[13] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
[14] 周婷, 孙培培, 张二明, 安欣华, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病诊断现状调查[J]. 中华临床医师杂志(电子版), 2023, 17(07): 790-797.
[15] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号